Vascular Therapies Stock

vasculartx.comBioTechFounded: 2001Funding to Date: $74.51MM

Vascular Therapies is a late-stage biopharmaceutical company focused on developing the Sirolimus-eluting collagen implant for local, perivascular drug delivery.

Register for Details

For more details on financing and valuation for Vascular Therapies, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Vascular Therapies.

Register Today
Register for Details

For more details on financing and valuation for Vascular Therapies, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

John McDermott
Chief Executive Officer & Board Member
Sriram Iyer MD
Founder, Chief Scientific Officer & Board Member
Paul Barkofsky Ph.D
Vice President, New Product Development
Rosanne Terraciano
Vice President, Operations
Maureen Harrison
Vice President, Quality Assurance

Board Members

Allan Tessler
Andrew Midler
Savitr Capital
Dan Ryan
Gerald Dorros MD
The Gerrald Dorros and Myra S. Dorros Recovable Trust
John McDermott
Kiyoshi Takesue
Michael Bamberger
Robert Croce
New Enterprise Associates
Robert Flanagan
Somasundaram Subramaniam
New Science Ventures
Sriram Iyer MD

Other companies like Vascular Therapies in the BioTech sector

Sector
 
 
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$185MM
Sector
Last Round Est. Valuation
$1.3B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.89B

News

/PRNewswire/ -- Vascular Therapies, a clinical stage biotechnology company, is developing Sirogen™, a proprietary sirolimus formulation for intraoperative...
Vascular Therapies has raised $12.4 million from 29 investors as part of a $21.1 million round, according to a document filed last week with the SEC. The Cresskill, N.J.-based company is developing a sirolimus-eluting collagen implant for patients with end-stage renal disease. The bioresorbable drug-delivery system is designed to keep open a portal of entry […]